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ABSTRACT
Allogeneic hematopoietic stem cell transplantation is frequently complicated by syndromes characterized by a
disruption of the endothelial integrity such as graft-versus-host disease or liver toxicity. Vascular endothelial
growth factor and activin-A, a member of the transforming growth factor beta (TGF-) superfamily, are
important for endothelial integrity and tissue repair. We retrospectively measured endogenous vascular
endothelial growth factor and activin-A serum levels in 70 patients following allogeneic stem cell transplan-
tation. Vascular endothelial growth factor serum levels were significantly decreased within the first 2 weeks
after the transplant and returned to pre transplant levels by day 15. Activin-A serum levels were significantly
elevated from day 7 with peak levels reached on day 10. By using the median value as cutoff high vascular
endothelial growth factor levels on day 15 were associated with significantly better overall survival, less liver
toxicity, faster neutrophil recovery, and a trend towards less severe acute graft-versus-host disease. No
correlation was found between activin-A serum levels and survival, liver toxicity, neutrophil recovery, or
graft-versus-host disease. Monitoring of vascular endothelial growth factor levels following allogeneic hema-
topoietic stem cell transplantation might help to identify patients with a very high risk for early transplant-
related complications.
© 2007 American Society for Blood and Marrow Transplantation
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SNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) is the treatment of choice for a variety of
therwise life-threatening diseases of the lympho-he-
atopoietic system. However, allogeneic SCT may be
omplicated by syndromes such as graft-versus-host
isease (GVHD) or chemo/radiotherapy-induced
iver toxicity resulting in substantial transplantation-
elated morbidity and mortality (TRM) [1]. Various
p- or dysregulated proinﬂammatory cytokines, endo-
helial markers, and coagulation parameters have been
iscussed to be involved in the endothelial injury ob-
erved in both syndromes [2-4]. Both vascular endo-
helial growth factor (VEGF) and activin-A, a member
f the transforming growth factor beta (TGF-) su-
erfamily, are known key players in vasopermeability w
42nd integrity, inﬂammation, repair, neovasculariza-
ion, and ﬁbrosis [5-7].
To better deﬁne the role of VEGF and activin-A
n the context of allogeneic HSCT and its complica-
ions we conducted a retrospective analysis of endog-
nous VEGF and activin-A serum concentrations in
he early posttransplant period following allogeneic
CT.
ATIENTS AND METHODS
atients
Seventy patients receiving an allogeneic hemato-
oietic SCT at our institution between May 1998 and
eptember 2004 after giving written informed consent
ere included in the study, which has been approved
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VEGF and Activin-A in Hematopoietic Stem Cell Transplantation 943y the local ethical committee. Detailed patient char-
cteristics are listed in Table 1. Conditioning regimen
ere myeloablative (n  48) or (RIC) (n  22) in case
f contraindication for conventional myeloablative
onditioning as deﬁned previously [8]. Donors were
ither human leukocyte antigen-identical siblings (n
8) or haploidentical family members (n  3) [9].
wenty-nine patients received a stem cell graft from a
olunteer unrelated donor. Only patients surviving
ore than 50 days after transplantation were included
n the analysis.
rophylaxis, Diagnosis, and Treatment of GVHD
Cyclosporine A (CSa) and methotrexate or myco-
henolate mofetil (MMF) were administered according
o the Seattle protocols for myeloablative or reduced-
ntensity transplants [10,11]. Patients receiving unrelated
tem cell grafts additionally received low-dose rabbit
ntithymocyte globulin (ATG) (Thymoglobulin®,
MTIX SangStat, Germany ) as described [12].
Acute and chronic GVHD (aGVHD, cGVHD)
ere diagnosed from clinical symptoms and/or bi-
psies from skin, oral mucosa, liver, or gut, and
lassiﬁed according to the previously published
tandard Seattle criteria [13,14]. aGVHD  grade
I was treated with steroids (2 mg/kg/day).
upportive Care
No prophylactic antibiotics were administered
able 1. Patient Characteristics
N
otal patient number 70
edian patient age, years (range) 40 (17-76)
edian donor age, years (range) 38 (15-79)
iagnosis
Acute leukemia 42
Chronic myelogenous leukemia 8
Lymphoma 7
Intermediate-, high-risk myelodysplastic
syndrome 6
Others 7
onor
HLA-identical sibling donor 38
Haploidentical family donor 3
Volunteer unrelated donor 29
onditioning regimen
Total-body irradiation containing 26
Busulfan-based 44
ex match
Male recipient/female donor 15
Others 55
tem cell source
Bone marrow 22
Peripheral blood 48
tage at transplantation
Standard risk 25
High risk 45uring neutropenia. All patients received Pneumocystis Viroveci pneumonia prophylaxis with trimethoprim-
ulfamethoxazole, 1 double-strength tablet 3 times
eekly until day 180 after transplantation. For Herpes
implex and Varicella-zoster virus prophylaxis patients
eceived either valacyclovir 500 mg twice daily orally
r low-dose acyclovir 250 mg/m2 intravenously 3 times
aily from the beginning of conditioning. Antifungal
rophylaxis consisted of ﬂuconazole 400 mg/day from
he beginning of conditioning until d 73 [15].
Irradiated (25 Gy) leukocyte-depleted random
latelet units from single donors and red cells were
ransfused when hemoglobin levels dropped to 8.0
/dL and platelet counts dropped to 20 g/L.
uantitative Determination of VEGF and
ctivin-A
Serum samples were collected every 4-7 days from
ay 4 until day 70 and stored at 70°C until use.
uman VEGF was detected by quantitative sandwich
nzyme immunoassay technique (R&D Systems, Inc.,
inneapolis, MN) with a detection limit of 25 pg/mL.
ctivin-A was measured by solid phase sandwich
LISA (Oxford Bio-Innovation Ltd, Oxfordshire,
K) with a detection limit of 0.076 ng/mL.
tatistical Methods
Statistical analyses were completed using the
ann-Whitney U-test for unpaired samples, the chi-
quare test for independence, and the Spearman rank
orrelation coefﬁcient using GraphPad Prism 4.0
GraphPad Software, Inc., San Diego, CA) with a 5%
evel of signiﬁcance.
Survival data were analyzed as of May 2006. Overall
urvival was calculated from the date of SCT to the date
f death from any cause or date of last follow-up. Prob-
bilities of overall survival (OS) were estimated using the
aplan-Meier method and compared using the log-rank
est [16]. Cumulative incidence estimates were calculated
or transplant-related mortality (TRM) and aGVHD
sing the NCSS statistical software package (Kaysville,
T) [17]. TRM was deﬁned as the probability of dying
ithout previous occurrence of relapse/progression,
hich is a competing event.
Median values of VEGF serum levels, activin-A
erum levels, and maximal total serum bilirubin were
sed as cutoff for categorization into high and low
alue groups.
A Cox regression was performed including recip-
ent age, donor age, time interval between diagnosis
nd SCT, CD34 cell dose, maximal total serum bili-
ubin, and number of days with a total serum bilirubin
2 mg/dL as continuous variables, and donor type
HLA-identical sibling versus others), risk category by
he underlying disease (standard versus high risk), sex
atch (male recipient/female donor versus others),
EGF serum level on day 15 (high versus low), and
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D. Nachbaur et al.944tem cell source (peripheral blood versus bone marrow
tem cells) as categoric variables. Standard-risk disease
as deﬁned as chronic myelogenous leukemia (CML)
n ﬁrst chronic phase and acute leukemia in ﬁrst com-
lete remission (CR1). All other indications were clas-
iﬁed as high-risk disease.
ESULTS
EGF and Activin-A Serum Levels
Mean VEGF serum levels were signiﬁcantly de-
reased during the ﬁrst 2 weeks with trough levels on
ay7 (61.5 4.5 pg/mL versus 315.5 48.4 pg/mL
n day 4, P  .0001) returning to pretransplant
evels by day 15. VEGF peak levels were measured
round day 40 (437  41 pg/mL, P  .02 versus
retransplant VEGF levels). In contrast, mean ac-
ivin-A serum levels were signiﬁcantly increased from
ay 7 through 70 with peak levels on day 10
0.717  0.103 ng/mL versus 0.422  0.034 ng/mL
ay 4, P  .0017) (Figure 1).
EGF and Activin-A Serum Levels, Neutrophil
ecovery, and CD34 Cell Count
Neutrophil recovery was deﬁned as the ﬁrst of 3
onsecutive days with a persistent absolute neutrophil
ount 0.5 G/L. Neutrophil recovery was signiﬁcantly
aster in patients with high VEGF levels (151.2 pg/
L) on day15 (median 11 [range, 8-16] days versus 15
range, 10-35] days, P  .0001, Mann-Whitney U-test),
hereas no such correlation could be demonstrated for
atients with high versus low day 10 activin-A serum
evels. There was also no correlation between pretrans-
lant VEGF or activin-A serum levels and time to neu-
rophil recovery (data not shown).
Because of patient number there was only a trend
or a faster neutrophil recovery in patients receiving a
igher number of CD34 stem cells (P  .08). There
as a highly signiﬁcant correlation between CD34 cell
ose and day 15 VEGF serum levels (r  0.5, P 
igure 1. Mean VEGF and activin-A serum levels  SE following
llogeneic hematopoietic SCT.0003). No such correlation was found between aD34 cell dose and day 10 activin-A serum levels
data not shown).
EGF and Activin-A Serum Levels and Liver
oxicity
Liver toxicity was assessed by maximal total serum
ilirubin levels, number of days with total serum bil-
rubin 2 mg/dL, and % maximal weight gain within
ay 20. The median maximum total serum bilirubin
efore day 20 was 2.89 (range, 0.72-15.45) mg/dL,
he median day number with a total serum bilirubin
mg/dL was 4.5 (range, 0-20) days, and the median
eight gain (% increase) was 4.2 (range, 0-17.6) per-
ent. Within the ﬁrst 2 weeks following transplant no
igniﬁcant correlation was found between VEGF se-
um levels and maximal total serum bilirubin or days
ith hyperbilirubinemia within day 20. From day
15 through day 70, however, VEGF serum levels
ere signiﬁcantly inverse correlated to maximal total
erum bilirubin levels and to the number of days with
otal serum bilirubin serum levels  2 mg/dL within
ay 20 (Figure 2a and b).
In contrast, no correlation was found between
ctivin-A levels and maximal total serum bilirubin or
igure 2. Correlation between VEGF serum levels on day15 and
, maximal total serum bilirubin and b, number of days with total
erum bilirubin  2 mg/dL within the ﬁrst 20 days following
llogeneic hematopoietic SCT.
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VEGF and Activin-A in Hematopoietic Stem Cell Transplantation 945ays with total serum bilirubin levels  2 mg/dL.
urthermore, no correlation was found between
EGF or activin-A serum levels measured at any time
oint (pre- or posttransplant) and % maximal weight
ain within day 20, respectively (data not shown).
EGF and Activin-A Serum Levels, OS, TRM,
nd Relapse Incidence
Overall survival at 4 years for the entire cohort was
9% (37%-61%, 95% conﬁdence interval, [CI]). By
nivariate analysis patients with a maximal total serum
ilirubin 2.89 mg/dL (ie, median) within day 20
ad a signiﬁcantly poorer outcome (OS 38%, 22%-
5%, 95% CI versus 61%, 44%-78%, 95% CI, for
atients with a maximal total serum bilirubin 2.89
g/dL; P  .02, log rank test) because of a higher
RM (35% versus 21%, P  .07, log-rank test). No
ifferences were observed between patients with high
r low maximal total serum bilirubin within day 20
ith regard to relapse incidence (data not shown).
To evaluate whether VEGF serum levels were asso-
iated with outcome, day15 levels were ﬁrst chosen for
he analysis because this time point was the earliest to
how a signiﬁcant correlation with parameters of liver
oxicity. The median value at the respective time point
as chosen to discriminate between “high” and “low”
alue groups. Patients with a day15 VEGF serum level
bove the median value of 151.2 pg/mL (ie, “high” value
roup) had a signiﬁcantly better OS of 65% (48%-82%,
5% CI) versus 29% (12%-45%, 95% CI) for patients
ith low VEGF serum levels (P  .0033, log rank test;
igure 3). This effect resulted from a lower TRM (22%
ersus 35%, P  .06, log-rank test) and a lower relapse
ncidence (25% versus 41%, P .05, log rank test) in the
igh-value group. If day40 VEGF levels were used for
he analysis a similar survival beneﬁt was observed for
atients with high VEGF serum levels ( 69%, 52%-
0,0
0,2
0,4
0,6
0,8
1,0
0 360 720 1080 1440 1800 2
days after SCT
%
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VEGF ≥ 151
VEGF < 151
p=0.0033, log rank test 
igure 3. Overall survival of patients with high versus low VEGF
edian value of VEGF (151 pg/mL) on day 15 was used to discr5%, 95% CI, versus 33%, 16%-50%, 95% CI, for fatients with low VEGF serum levels, P  .0067, log-
ank test). However, in contrast to earlier time points
fter the transplant, this survival beneﬁt was only the
esult of a lower TRM (15% versus 35%), whereas
elapse incidence was similar in both cohorts (36% ver-
us 31%).
Pretransplant VEGF and activin-A serum levels as
ell as activin-A serum levels on day 10 had no
igniﬁcant impact on OS, TRM, relapse (data not
hown).
EGF and Activin-A Serum Levels and aGVHD
Overall, the cumulative incidence of aGVHD
rades II-IV was 64% (54%-77%, 95% CI) with no
igniﬁcant differences in the incidence with respect to
onor type (HLA-identical sibling versus others),
tem cell source (peripheral blood versus bone mar-
ow), or conditioning regimen (myeloablative versus
IC) (data not shown). There were also no signiﬁcant
ifferences in the cumulative incidence of aGVHD
rades II-IV in patients with high or low VEGF levels
ither pretransplant or on day15, or in patients with
igh or low activin-A serum levels either pretransplant
r on day 10 (data not shown). There was a trend
owards less severe aGVHD grades III-IV in patients
ith high day 15 VEGF levels (P  .07, chi-square
est). There was no signiﬁcant difference in the inci-
ence of aGVHD grades II-IV requiring steroid treat-
ent before day 15 between patients with high or
ow day 15 VEGF levels (16% versus 28%, P  .2
hi-square test).
ultivariate Analysis
By multivariate Cox regression standard-risk dis-
ase was the most powerful predicitve parameter for a
ower risk for death (relative risk 0.1126, P  .02)
20 2880 3240
L, overall survival 65% (48%-82%, 95% CI)
L ,  overall survival 29% (12%-45%, 95% CI)
levels on day 15 following allogeneic hematopoietic SCT. The
e between patients with high and low VEGF levels.160 25
.2 pg/m
.2 pg/m
serumollowed by high day 15 serum VEGF levels (rela-
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D. Nachbaur et al.946ive risk 0.1936, P .02) There was a trend for a lower
isk for death in patients with an HLA-identical sib-
ing donor (relative risk 0.3913, P  .08) (Table 2).
ISCUSSION
In the present analysis higher VEGF serum levels
fter hematopoietic regeneration following allogeneic
CT were associated with a signiﬁcantly better OS.
ven by multivariate Cox regression analysis higher
EGF serum level on day 15 remained a signiﬁcant
arameter for a lower risk for death.
This survival advantage in patients with high (ie,
reater than the median value) VEGF levels on day
15 following allogeneic SCT resulted from a lower
RM and a lower relapse incidence. A lower 1-year
onrelapse mortality (NRM) for patients with low
EGF levels between day7 and day14 has already
een observed by Min and coworkers [18], although
hey did not comment on survival in their cohort. The
nterrelation between VEGF and relapse incidence is
ot clear, and warrants further investigations. It can at
east partly be explained by the fact that signiﬁcantly
ore high-risk patients belonged to the cohort of
atients with low day 15 VEGF serum levels com-
ared with patients with high day 15 VEGF levels
data not shown). However, when day 40 VEGF
evels were used for the analysis instead of day15
alues the difference in relapse incidence between
igh and low value groups disappeared, whereas the
ffects on survival and TRM remained signiﬁcant,
uggesting that over time VEGF levels become more
mportant for transplant-related complications than
or relapse.
One of these complications is liver toxicity, which
s usually thought to be caused by disturbances of
arious coagulation parameters and/or inﬂammatory
ytokines, resulting in endothelial injury [3,4]. From
n initial report in 6 patients with typical manifesta-
able 2. Multivariate Cox Regression Analysis for the Risk of Death fo
Variable
ontinuous
Time interval between diagnosis and HSCT
CD34 cell dose
Recipient age
Donor age
Maximal total serum bilirubin
Number of days with bilirubin >2 mg/dL
ategorical
HLA-identical sibling donor
Standard-risk disease
Peripheral blood stem cells
Male recipient/female donor
High d15 VEGF serum level
EGF indicates vascular endothelial growth factor.ions of veno-occlusive disease it was postulated that oEGF might be 1 of the cytokines predictive and
ausative for hepatic veno-occlusive disease [19]. Our
esults, however, in a substantially larger group of
atients do not conﬁrm these initial ﬁndings, because
igh VEGF levels were signiﬁcantly correlated with
ess liver toxicity and signiﬁcantly fewer days with
levated serum bilirubin within the ﬁrst 20 days.
GVHD is another frequent complication follow-
ng allogeneic SCT, resulting in signiﬁcant trans-
lant-related morbidity and TRM. Similar to our re-
ults, a trend for a lower incidence of severe aGVHD
ie, grades III-IV) in patients with high day 15
EGF levels has already been described by Min et al.
18]. Together, these ﬁndings do not support a role of
irculating endogenous VEGF in the cytokine net-
ork involved in the pathogenesis of aGVHD [20,21].
hether steroids affect VEGF serum levels is cur-
ently unknown. At least in our cohort there were no
igniﬁcant differences in the percentage of patients
eceiving steroid treatment because of aGVHD before
ay 15 between high or low day 15 VEGF value
roups.
Another important ﬁnding of our study is the
orrelation between VEGF levels, CD34 cell dose,
nd neutrophil recovery, suggesting that upcoming
onor-derived peripheral blood cells are the main
ource of circulating endogenous VEGF following
llogeneic SCT [22,23]. Interestingly, by multivariate
ox regression analysis, high day 15 VEGF levels
ere signiﬁcantly more predeictive for a better out-
ome after transplant than CD34 cell dose in the
espective model.
The second cytokine that was analyzed in our
tudy was activin-A, a member of the TGF- family.
lthough increased active-A serum levels after day
10 suggest a possible role in general repair following
llogeneic HSCT, we failed to demonstrate any cor-
elation between activin-A serum levels and survival,
iver toxicity, hematopoietic recovery, or GVHD in
Allogeneic Hematopoietic Stem Cell Transplantation
Relative Risk P Value
1.0002 (0.9999-1.0006) .22
0.9852 (0.8990-1.0796) .75
0.9857 (0.9439-1.0293) .51
0.9994 (0.9488-1.0528) .98
1.1677 (0.8850-1.5408) .27
0.9059 (0.7840-1.0467) .18
0.3913 (0.1391-1.1009) .08
0.1126 (0.0174-0.7284) .02
1.1527 (0.0967-13.7363) .91
1.7870 (0.3425-7.3855) .42
0.1936 (0.0503-0.7442) .02llowingur patient cohort [24]. Whether activin-A might be
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VEGF and Activin-A in Hematopoietic Stem Cell Transplantation 947nvolved in later stages of liver toxicity when stellate
ell proliferation and collagenization by types I, III,
nd IV collagen take place remains to be shown [25].
n vitro studies have demonstrated a stimulatory effect
f activin-A on collagen type I messenger RNA ex-
ression, and elevations of procollagen propeptide has
een observed in patients with veno-occlusive disease
26,27]. Moreover, elevated plasma TGF- levels
rior to autologous SCT have been reported to be
trongly correlated with the development of hepatic
eno-occlusive disease [28].
In conclusion, although the presented data must
e considered, preliminary, patients with high post
ransplant VEGF levels showed improved survival, a
aster neutrophil recovery, less liver toxicity, and less
evere aGVHD. Patients with low posttransplant
EGF levels represent a high-risk cohort of patients
ith a higher relapse rate and/or a higher TRM.
onitoring VEGF serum levels following allogeneic
CT might help to identify patients at a very high risk
or early death.
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